FAIRFIELD, N.J., June 12 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced the launch of its authorized generic version for ADOXA(R) 150 mg strength doxycycline monohydrate tablets. In accordance with a licensing and distribution agreement with Par Pharmaceutical Companies, Inc., Par began immediate shipments of the 150 mg strength tablets after the approval of another generic product. ADOXA(R) is an antibiotic therapy primarily used for the treatment of acne.
“While this strength of ADOXA(R) represented approximately 18.5% of Bradley’s 2006 net sales, we proactively planned for this launch to commence once a generic version became available,” stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals. “Since 2005, Par has been our exclusive partner with authorized generic ADOXA(R) formulations and maintains about a 55% market share of previous formulations of ADOXA(R) generics, including the 50 mg and 100 mg strengths of ADOXA(R).”
Important Product Safety Information About ADOXA(R):
ADOXA(R) Tablets are contraindicated in persons who have shown any sensitivity to any of the tetracyclines. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to 8 years) may cause permanent discoloration of the teeth (yellow-gray- brown). Photosensitivity manifested by exaggerated sunburn has been observed in some individuals taking tetracyclines. Treatment should be discontinued at first evidence of skin erythema. Concurrent use of tetracycline may render oral contraceptives less effective.
For additional important information about ADOXA(R), please view full prescribing information at www.bradpharm.com or request full prescribing information by contacting Bradley Pharmaceuticals.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
About Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Safe Harbor for Forward-Looking Statements:
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley’s plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley’s products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to: launch VEREGEN(TM) at the end of 2007 and ELESTRIN(TM) at the end of the second quarter 2007; predict the safety and efficacy of these products in a commercial setting; estimate sales; maintain adequate inventory levels; implement the returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Cecelia C. Heer, Investor, Public Relations of BradleyPharmaceuticals, Inc., +1-973-882-1505, ext. 252, cheer@bradpharm.com
Web site: http://www.bradpharm.com/
